Jove
Visualize
Contact Us

Related Experiment Videos

Optimizing lipid lowering in patients at risk.

Luther T Clark1

  • 1Division of Cardiovascular Medicine, State University of New York Downstate Medical Center, Brooklyn, New York 11203-2098, USA. ltclark@downstate.edu

Clinical Cardiology
|July 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing the Science of Patient Input in Drug Research and Development.

Journal of participatory medicine·2026
Same author

The association between social determinants of health and patient-centred outcomes in adults with heart failure with reduced ejection fraction.

Journal of advanced nursing·2023
Same author

Enhancing Diversity and Inclusion in Clinical Trials.

Clinical pharmacology and therapeutics·2023
Same author

Patient-centered Outcomes in HFrEF Following a Worsening Heart Failure Event: A Survey Analysis.

Journal of cardiac failure·2021
Same author

Corrigendum to ``Increasing Diversity in Clinical Trials: Overcoming Critical Barriers''. [Current Problems in Cardiology, Volume 44, Issue 5 (2019) 148-172].

Current problems in cardiology·2020
Same author

US Cancer Centers of Excellence Strategies for Increased Inclusion of Racial and Ethnic Minorities in Clinical Trials.

Journal of oncology practice·2019
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Aggressively lowering LDL cholesterol (low-density lipoprotein cholesterol) with statins and ezetimibe offers greater lipid improvements than statins alone. This combination therapy helps more patients reach treatment goals for cardiovascular health.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Metabolic Disorders

Background:

  • Statins are effective for lowering low-density lipoprotein cholesterol (LDL-C) and reducing coronary heart disease risk.
  • Emerging evidence suggests more intensive lipid management may offer additional clinical benefits beyond current LDL-C goals.

Purpose of the Study:

  • To explore the efficacy of combining cholesterol absorption inhibitors (like ezetimibe) with statins for aggressive LDL-C reduction.
  • To evaluate the benefits of simultaneously inhibiting cholesterol synthesis and absorption for improved lipid profiles.

Main Methods:

  • Clinical trials comparing combination therapy (statin + ezetimibe) with statin monotherapy.
  • Assessment of lipid parameters, including LDL-C, and achievement of treatment goals.

Related Experiment Videos

Main Results:

  • Combination therapy resulted in significantly greater LDL-C reductions compared to statin monotherapy.
  • A higher percentage of patients achieved their lipid treatment goals with the combination therapy.
  • Potential additional benefits include reduction of phytosterols, chylomicron remnants, and C-reactive protein.

Conclusions:

  • Combining cholesterol absorption inhibitors with statins is an effective strategy for aggressive LDL-C lowering.
  • This approach enhances lipid improvements and helps more patients achieve therapeutic targets.
  • Ongoing research is investigating if these lipid benefits translate to improved clinical outcomes.